Previous studies in vivo (14, 15) and in vitro (16, 26, 27) suggested that EGFR might be a therapeutic target also in FOSCC, prompting us to test the anti-cancer potential of Cetuximab in well-characterized cell lines derived from this tumor (17–19). The gene discussed is EGFR; the disease is neoplasm.